Skip to main content
Erschienen in:

07.03.2022 | main topic

Experimental laboratory biomarkers in multiple sclerosis

verfasst von: Borros Arneth, Jörg Kraus

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2022

Einloggen, um Zugang zu erhalten

Summary

Background

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system; the cause of this condition remains unknown. Researchers have analyzed different biomarkers related to MS. Here, experimental laboratory biomarkers for MS are identified and analyzed.

Methods

The current study examined articles investigating biomarkers for MS. Records were obtained from the PubMed, LILACS, and EBSCO databases using an identical search strategy and terms that included “multiple sclerosis,” “MS,” and “biomarkers.” In the current review, we also focus on lesser known biomarkers that have not yet been established for use in clinical practice.

Results

Previous studies have explored molecular substances that may help diagnose MS and manage its adverse effects. Commonly studied factors include neurofilaments, sCD163, CXCL13, NEO, NF‑L, OPN, B cells, T cells, and integrin-binding proteins.

Conclusions

Interactions between environmental and genetic factors have been implicated in the development of MS. Previous investigations have identified a wide range of biomarkers that can be used for diagnosis and disease management. These molecules and their associated studies provide vital insight and data to help primary physicians improve clinical and health outcomes for MS patients.
Literatur
1.
Zurück zum Zitat von Büdingen HC, Gulati M, Kuenzle S, Fischer K, Rupprecht TA, Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands. J Neuroimmunol. 2010;218(1–2):134–9.CrossRef von Büdingen HC, Gulati M, Kuenzle S, Fischer K, Rupprecht TA, Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands. J Neuroimmunol. 2010;218(1–2):134–9.CrossRef
2.
Zurück zum Zitat Thompson S, Jones J, Cox A, Compston D, Coles A. B‑cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99–105.PubMedCrossRef Thompson S, Jones J, Cox A, Compston D, Coles A. B‑cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99–105.PubMedCrossRef
6.
Zurück zum Zitat Wang H, Naghavi M, Allen C, Barber R, Bhutta Z, Carter A, et al. GBD 2015 mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459–544.CrossRef Wang H, Naghavi M, Allen C, Barber R, Bhutta Z, Carter A, et al. GBD 2015 mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459–544.CrossRef
7.
Zurück zum Zitat Sormani MP, Signori A, Siri P, De Stefano N. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler. 2013;19:466–74.PubMedCrossRef Sormani MP, Signori A, Siri P, De Stefano N. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler. 2013;19:466–74.PubMedCrossRef
19.
Zurück zum Zitat Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64:428–33.PubMedCrossRef Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64:428–33.PubMedCrossRef
20.
Zurück zum Zitat Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with higher relapse risk in multiple sclerosis. Neurology. 2012;79:261–6.PubMedCrossRef Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with higher relapse risk in multiple sclerosis. Neurology. 2012;79:261–6.PubMedCrossRef
22.
Zurück zum Zitat Teunissen CE, Iacobaeus E, Khademi M. Combination of CSF N‑acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322–9.PubMedCrossRef Teunissen CE, Iacobaeus E, Khademi M. Combination of CSF N‑acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322–9.PubMedCrossRef
24.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.PubMedCrossRef Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.PubMedCrossRef
26.
Zurück zum Zitat Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta-1a. Ann Neurol. 2003;53:718–24.PubMedCrossRef Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta-1a. Ann Neurol. 2003;53:718–24.PubMedCrossRef
27.
Zurück zum Zitat Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292–303.PubMedPubMedCentralCrossRef Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292–303.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206–13.PubMedCrossRef Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011;76(14):1206–13.PubMedCrossRef
31.
Zurück zum Zitat Comabella M, Montalbana X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113–26.PubMedCrossRef Comabella M, Montalbana X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014;13:113–26.PubMedCrossRef
32.
Zurück zum Zitat Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18(5):552–6.PubMedCrossRef Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler. 2012;18(5):552–6.PubMedCrossRef
33.
Zurück zum Zitat Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010;16(3):287–92.PubMedCrossRef Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010;16(3):287–92.PubMedCrossRef
34.
Zurück zum Zitat Martinez MA, Olsson B, Bau L. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550–61.PubMedPubMedCentralCrossRef Martinez MA, Olsson B, Bau L. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550–61.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Modvig S, Degn M, Sander B. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016;22(5):590–8.PubMedCrossRef Modvig S, Degn M, Sander B. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016;22(5):590–8.PubMedCrossRef
38.
Zurück zum Zitat Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230–7.PubMedPubMedCentralCrossRef Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230–7.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Gama PD, Machado LD, Livramento JA, Gomes HR, Adoni T, Lino AM, et al. Study of oligoclonal bands restricted to the cerebrospinal fluid in multiple sclerosis patients in the city of São Paulo. Arq Neuropsiquiatr. 2009;67:1017–22.PubMedCrossRef Gama PD, Machado LD, Livramento JA, Gomes HR, Adoni T, Lino AM, et al. Study of oligoclonal bands restricted to the cerebrospinal fluid in multiple sclerosis patients in the city of São Paulo. Arq Neuropsiquiatr. 2009;67:1017–22.PubMedCrossRef
40.
Zurück zum Zitat Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. Potassium channel KIR4. 1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367(2):115–23.PubMedPubMedCentralCrossRef Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. Potassium channel KIR4. 1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367(2):115–23.PubMedPubMedCentralCrossRef
41.
42.
Zurück zum Zitat Toscano S, Patti F. CSF biomarkers in multiple sclerosis: beyond neuroinflammation. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):14–41. Toscano S, Patti F. CSF biomarkers in multiple sclerosis: beyond neuroinflammation. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):14–41.
43.
Zurück zum Zitat Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, Otto M, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One. 2014;9(4):e88680.PubMedPubMedCentralCrossRef Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, Otto M, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One. 2014;9(4):e88680.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Senel M, Mojib-Yezdani F, Braisch U, Bachhuber F, Lewerenz J, Ludolph AC, et al. CSF free light chains as a marker of intrathecal immunoglobulin synthesis in multiple sclerosis: a blood-CSF barrier related evaluation in a large cohort. Front Immunol. 2019;10:641.PubMedPubMedCentralCrossRef Senel M, Mojib-Yezdani F, Braisch U, Bachhuber F, Lewerenz J, Ludolph AC, et al. CSF free light chains as a marker of intrathecal immunoglobulin synthesis in multiple sclerosis: a blood-CSF barrier related evaluation in a large cohort. Front Immunol. 2019;10:641.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Schwenkenbecher P, Konen FF, Wurster U, Jendretzky KF, Gingele S, Sühs KW, et al. The persisting significance of oligoclonal bands in the dawning era of kappa free light chains for the diagnosis of multiple sclerosis. Int J Mol Sci. 2018;19(12):3796.PubMedCentralCrossRef Schwenkenbecher P, Konen FF, Wurster U, Jendretzky KF, Gingele S, Sühs KW, et al. The persisting significance of oligoclonal bands in the dawning era of kappa free light chains for the diagnosis of multiple sclerosis. Int J Mol Sci. 2018;19(12):3796.PubMedCentralCrossRef
48.
Zurück zum Zitat Comabella M, Craig DW, Morcillo-Suárez C. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009;66:972–8.PubMedCrossRef Comabella M, Craig DW, Morcillo-Suárez C. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009;66:972–8.PubMedCrossRef
49.
Zurück zum Zitat Thebault S, Abdoli M, Fereshtehnejad SM, Tessier D, Tabard-Cossa V, Freedman MS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020;10(1):1–1.CrossRef Thebault S, Abdoli M, Fereshtehnejad SM, Tessier D, Tabard-Cossa V, Freedman MS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020;10(1):1–1.CrossRef
50.
Zurück zum Zitat Bushnell SE, Zhao Z, Stebbins CC. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology. 2012;79:531–7.PubMedPubMedCentralCrossRef Bushnell SE, Zhao Z, Stebbins CC. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology. 2012;79:531–7.PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Sanz Diaz CT, de las Heras Flórez S, Carretero Perez M, Hernández Pérez MÁ, Martín García V. Evaluation of kappa index as a tool in the diagnosis of multiple sclerosis: implementation in routine screening procedure. Front Neurol. 2012;12:1259. Sanz Diaz CT, de las Heras Flórez S, Carretero Perez M, Hernández Pérez MÁ, Martín García V. Evaluation of kappa index as a tool in the diagnosis of multiple sclerosis: implementation in routine screening procedure. Front Neurol. 2012;12:1259.
54.
Zurück zum Zitat Stilund M, Gjelstrup MC, Petersen T, Møller HJ, Rasmussen PV, Christensen T. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One. 2015;10(4):e119681.PubMedPubMedCentralCrossRef Stilund M, Gjelstrup MC, Petersen T, Møller HJ, Rasmussen PV, Christensen T. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One. 2015;10(4):e119681.PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA. Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol. 2010;229:263–71.PubMedCrossRef Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA. Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol. 2010;229:263–71.PubMedCrossRef
56.
Zurück zum Zitat Durante L, Zaaraoui W, Rico A. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler. 2012;18:587–91.PubMedCrossRef Durante L, Zaaraoui W, Rico A. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler. 2012;18:587–91.PubMedCrossRef
57.
Zurück zum Zitat Ferraro D, Simone AM, Bedin R. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with the clinically isolated syndrome. J Neuroimmunol. 2013;257:76–81.PubMedCrossRef Ferraro D, Simone AM, Bedin R. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with the clinically isolated syndrome. J Neuroimmunol. 2013;257:76–81.PubMedCrossRef
59.
Zurück zum Zitat Khademi M, Kockum I, Andersson ML. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2012;17:335–43.CrossRef Khademi M, Kockum I, Andersson ML. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2012;17:335–43.CrossRef
60.
Zurück zum Zitat Zhong X, Wang H, Dai Y. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol. 2012;240–241:104–8. Zhong X, Wang H, Dai Y. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol. 2012;240–241:104–8.
61.
Zurück zum Zitat Schmidt C, Plate A, Angele B. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2013;76:1051–8.CrossRef Schmidt C, Plate A, Angele B. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2013;76:1051–8.CrossRef
62.
Zurück zum Zitat Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2012;75:208–16.CrossRef Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2012;75:208–16.CrossRef
63.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2013;358:676–88.CrossRef Hauser SL, Waubant E, Arnold DL. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2013;358:676–88.CrossRef
64.
Zurück zum Zitat Naismith RT, Piccio L, Lyons JA. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2012;74:1860–7.CrossRef Naismith RT, Piccio L, Lyons JA. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2012;74:1860–7.CrossRef
65.
Zurück zum Zitat Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G. Neural cell adhesion molecule—description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. J Neuroimmunol. 2010;225:118–22.PubMedCrossRef Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G. Neural cell adhesion molecule—description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. J Neuroimmunol. 2010;225:118–22.PubMedCrossRef
67.
Zurück zum Zitat Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335–43.PubMedCrossRef Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335–43.PubMedCrossRef
68.
Zurück zum Zitat Dobson R, Topping J, Davis A, Thompson E, Giovannoni G. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand. 2013;128(5):321–7.PubMed Dobson R, Topping J, Davis A, Thompson E, Giovannoni G. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand. 2013;128(5):321–7.PubMed
69.
Zurück zum Zitat Cenit MD, Blanco-Kelly F, de las Heras V. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler. 2009;15:913–7.PubMedCrossRef Cenit MD, Blanco-Kelly F, de las Heras V. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler. 2009;15:913–7.PubMedCrossRef
71.
Zurück zum Zitat Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021–7.PubMedCrossRef Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021–7.PubMedCrossRef
72.
Zurück zum Zitat Romme Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler. 2013;19(7):877–84.PubMedCrossRef Romme Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler. 2013;19(7):877–84.PubMedCrossRef
73.
Zurück zum Zitat Bahlo M, Booth DR, Broadley S, Brown MA, Foote SJ, Griffiths LR, et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41(7):824–8.CrossRef Bahlo M, Booth DR, Broadley S, Brown MA, Foote SJ, Griffiths LR, et al. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41(7):824–8.CrossRef
74.
Zurück zum Zitat Schwartz ES, Chapman BP, Duberstein PR, Weinstock-Guttman B, Benedict RH. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment. 2011;18(1):39–49.PubMedCrossRef Schwartz ES, Chapman BP, Duberstein PR, Weinstock-Guttman B, Benedict RH. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment. 2011;18(1):39–49.PubMedCrossRef
75.
Zurück zum Zitat The ANZgene Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824–8.CrossRef The ANZgene Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824–8.CrossRef
76.
Zurück zum Zitat Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):66–8.CrossRef Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B‑cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):66–8.CrossRef
77.
Zurück zum Zitat Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):32–41. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):32–41.
79.
Zurück zum Zitat Canwell B, Bar-Or A, Arnold DL. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011;10:436–45.CrossRef Canwell B, Bar-Or A, Arnold DL. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011;10:436–45.CrossRef
80.
Zurück zum Zitat Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134(2):34–41.CrossRef Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134(2):34–41.CrossRef
82.
Zurück zum Zitat Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406–19.PubMedCrossRef Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406–19.PubMedCrossRef
83.
Zurück zum Zitat Mowry EM, Waubant E, McCulloch CE. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72:234–40.PubMedPubMedCentralCrossRef Mowry EM, Waubant E, McCulloch CE. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72:234–40.PubMedPubMedCentralCrossRef
84.
85.
Zurück zum Zitat Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.PubMedPubMedCentralCrossRef Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010;133(6):1602–11.PubMedCrossRef Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010;133(6):1602–11.PubMedCrossRef
Metadaten
Titel
Experimental laboratory biomarkers in multiple sclerosis
verfasst von
Borros Arneth
Jörg Kraus
Publikationsdatum
07.03.2022
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2022
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00920-7

Weitere Artikel der Ausgabe 15-16/2022

Wiener Medizinische Wochenschrift 15-16/2022 Zur Ausgabe